The MASTL-ENSA-PP2A/B55 axis modulates cisplatin resistance in oral squamous cell carcinoma
Platinum-based chemotherapy is the standard first-line treatment for oral squamous cell carcinoma (OSCC) that is inoperable, recurrent, or metastatic. Platinum sensitivity is a major determinant of patient survival in advanced OSCC. Here, we investigated the involvement of MASTL, a cell cycle kinase...
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Frontiers Media S.A.
2022-09-01
|
| Collection: | Frontiers in Cell and Developmental Biology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fcell.2022.904719/full |